Save your brain: Do your homework Chicago Flame Online (subscription), IL - Alzheimer's Disease, known to some as 'Old Timer's,' has been around since the 1900s when it was first diagnosed by Dr. Alois Alzheimer. ...
Study links asthma rate to birth month Boston Globe, United States - The same is true of Alzheimer's patients, adults with brain tumors, and children with congenital valvular heart disease. So does it make sense for parents ...
The case for Pfizer CNNMoney.com - 57 minutes ago The company has also shifted its focus from obesity and heart disease to lucrative fields such as Alzheimer's and cancer, which are more cost-prohibitive to ...
Drugs you can't have Stuff.co.nz, New Zealand - Nov 30, 2008 A class of drugs touted as potential treatments for Alzheimer's disease. There are three variants: donepezil (marketed as Aricept) rivastigmine (Exelon) and ...
What's in a Name? When It Comes to Drugs, Plenty Washington Post, United States - And the Alzheimer's drug Reminyl was changed to Razadyne after mix-ups involving Amaryl, which lowers blood sugar. The mix-ups reportedly resulted in two ...
Innovative Alzheimer's medications offer hope Connecticut Post, CT - Currently, there are two groups of drugs on the market to treat Alzheimer's. One type blocks an enzyme responsible for the breakdown of a chemical, ...
Can Alzheimer's drug halt progress? Healthcare Republic - Aug 6, 2008 A new drug can slow Alzheimer's disease progression by up to 80 per cent, according to reports. Experimental drug Rember, the first of its kind to target ...
Alzheimer drug slows cognitive decline Irish Times, Ireland - Aug 4, 2008 A NEW DRUG has slowed cognitive decline by up to 81 per cent in Alzheimer patients during early pharmaceutical trials, it has been announced. ...
[CITATION] Growing evidence for memantine treatment of Alzheimer's related dementia A Pirisi, D Dye
Epoetin alfa has potential efficacy in central nervous system disorders - A Cerami, M Brines, C Cerami - EJC Supplements, 2004 - Elsevier ... It was postulated that the drug has a potential for treatment of ... such as ischemic
stroke, epilepsy, Parkinson's disease, Alzheimer's disease and ... 32395?32400. ...
Presenilin-1 gene promoter - MP Vitek, N Mitsuda, AD Roses - US Patent 6,255,473, 2001 - freepatentsonline.com ... for studying the function of the Presenilin-1 gene, for studying the etiology of Alzheimer's disease, and for studying the activity of various drugs and drug...
Transgenic animal assay system for anti-cholinesterase substances - H Soreq, H Zakut, M Shani - US Patent 6,025,183, 2000 - freepatentsonline.com ... " Drug. ... Anti-cholinesterase drugs are employed to treat a variety of diseases including Alzheimer's and Parkinson's diseases, glaucoma, multiple sclerosis, and ...
Method for identifying apoptosis modified proteins - EP Patent 1,764,616, 2007 - freepatentsonline.com ... during apoptosis can be used to screen drugs which activate or inhibit their activity
and which are useful in prevention and/or treatment of Alzheimer's disease ... -
Modulation of excitable tissue function by peripherally administered erythropoietin - C Cerami, A Cerami, M Brines - US Patent 7,345,019, 2008 - freepatentsonline.com ... Chem. 272:32395-32400. ... growth hormone deficiency, hypocortisolism, drug overdose,
and ... sclerosis, hypotension, cardiac arrest, Alzheimer's disease, Parkinson's ...
- M Brines, A Cerami, C Cerami - US Patent 7,309,687, 2007 - Google Patents ... Chem. 272:32395-32400. ... Nephrol. 9(suppl. 2): 12-15. Pardridge, 1997, "Drug delivery
to the brain", J. Cerebral Blood Flow Metab. 17:713-731. ... -
Fused - F de Sauvage, A Rosenthal - US Patent 6,022,708, 2000 - freepatentsonline.com ... Myers (1996) Human sequence tagged site SHGC-32400. GenBank accession No. G27519. ...
The screened molecules preferably are small molecule drug candidates. ...
Source: Google Scholar
Anti-inflammatory activity of Alzheimer's disease drugs discovered
The mechanism of anti-Alzheimer's disease drugs that inhibits the production of a destructive, inflammation-causing protein in the brain has been revealed by researchers at the Hebrew University of Jerusalem.
Their work, described in the Annals of Neurology, is likely to lead to the development of more efficient drugs than are currently in use for treating Alzheimer's disease as well as other neurological conditions resulting from infections, autoimmune diseases such as multiple sclerosis, or brain inflammation resulting from trauma or stroke.
Alzheimer's disease is a degenerative disease of the brain, characterized by a deterioration of both cognitive and physical abilities. It first affects memory and the ability to carry out complex, coordinated tasks. It also can bring on depression, inattention and outbursts of anger. In a more progressive stage, the disease can cause difficulties in the ability to perform even simple tasks such as speaking and comprehending, eating and sleeping. The affected person can even forget his name and identity.
The medicines administered today to Alzheimer's Disease patients focus on preventing the breakdown of acetylcholine, a chemical produced by brain cells which transmits information within the brain and is vitally involved in cognitive processes that include memory, attention and thought. Because acetylcholine-producing cells are among the first to die in Alzheimer's Disease patients, drug-induced elevation of acetylcholine levels partially attenuates the cognitive deterioration.
In recent years it has been shown that another pathological process that occurs in the brain of Alzheimer's disease patients is excessive immune activation and inflammation, which are induced by overproduction of an inflammation-producing protein called interleukin-1, as well as a few other related compounds. This process can impair the functioning of nerve cells and can even lead to their death. Furthermore, genetic alterations in the interleukin-1 gene have been associated with increased risk for the appearance and severity of Alzheimer's disease symptoms.
The Hebrew University researchers found that anti-Alzheimer's disease drugs currently in use not only block the activity of the enzyme responsible for breaking down acetylcholine but also cause a marked reduction in the production of interleukin-1. Furthermore, they describe the use of a novel drug ( EN101 ), developed by Hermona Soreq's team, which produces these effects in a more efficient way than known heretofore by destroying the molecular antecedent ( messenger RNA ) of the enzyme, rather than simply blocking the enzyme's activity.
In a series of experiments, conventional anti-Alzheimer's disease drugs, as well as the novel drug EN101, were injected into mice with brain inflammation. It was found that these injections reduced significantly the activity of the enzyme that breaks down acetylcholine and blocked almost entirely the production of interleukin-1.
" These findings suggest a new role for acetylcholine in the brain," said Raz Yirmiya. " When the anti-Alzheimer's disease drugs block the enzyme which breaks down acetylcholine, the level of this chemical in the brain goes up, and there is a reduction of the production of the inflammatory material, interleukin-1, and its destructive influence in the brain."
